Clinical trials
Lung Cancer Stage I clinical trials
Below are recruiting lung cancer stage i clinical trials, each written for real people, not researchers. We’re tracking 1,117 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05789082RecruitingPhase 1/Phase 2
Divarasib for untreated lung cancer with KRAS G12C
This trial studies divarasib to see if it is safe and can shrink or control advanced lung cancer. Participants must have a KRAS G12C mutation and have not had prior treatment for their advanced disease.
Duarte, CaliforniaAges 18 years+ - NCT06223711RecruitingPhase 2
Durvalumab with radiation therapy for limited-spread small cell lung cancer
This trial tests a combination of durvalumab (immunotherapy) plus radiation and chemotherapy for people with extensive-stage small cell lung cancer that has only a few distant spots. The goal is to see if this approach helps control the cancer better.
Augsburg, BavariaAges 18 years+ - NCT07459634RecruitingPhase 2
Combination treatment for extensive-stage small cell lung cancer
This trial tests a combination of two drugs—lurbinectedin and durvalumab—for people with extensive-stage small cell lung cancer who have already received initial treatment. The goal is to see if this combination can help control the cancer better.
Los Angeles, CaliforniaAges 18 years+ - NCT06536868RecruitingPhase 2
Tislelizumab with chemo and radiation for extensive-stage small cell lung cancer
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and chest radiation for people with extensive-stage small cell lung cancer (SCLC) that has spread. The goal is to see if this combination helps shrink or control the cancer longer.
Jincheng, ShanxiAges 18–80 - NCT05692999RecruitingPhase 3
Maintenance pembrolizumab dose study for non-squamous lung cancer
This Phase 3 trial tests two maintenance schedules (“usual” dose versus a lower dose) of pembrolizumab after your initial chemotherapy with pembrolizumab. It aims to see if the lower dose works well enough to control cancer while possibly reducing side effects.
NamurAges 18 years+ - NCT07783971Recruiting
Lung cancer microbiome study
This study looks at the bacteria and other microbes in lung cancer tissue to understand how they might affect the disease. It may help find new ways to treat or manage non-small cell lung cancer.
Chongqing, Liangjiang NewAges 30–80 - NCT07566052RecruitingPhase 3
Comparing a new KRAS drug to docetaxel for advanced lung cancer
This trial tests a new pill (setidegrasib) against a standard chemo drug (docetaxel) for people with a specific type of advanced lung cancer that has a KRAS G12D mutation. The goal is to see which treatment works better.
Glendale, CaliforniaAges 18 years+ - NCT07401498Enrolling by invitation
Studying side effects of lymph node removal in lung cancer surgery
This trial looks at complications from removing lymph nodes during surgery for non-small cell lung cancer. It may help doctors understand how to make surgery safer.
UlyanovskAges 18 years+ - NCT07288632Recruiting
Lung cancer gene test and blood clot risk study
This study looks at whether certain gene profiles in advanced lung cancer affect the risk of blood clots. It may help doctors better understand and prevent clots in people starting new cancer treatment.
Perugia, PerugiaAges 18 years+ - NCT06514027RecruitingPhase 2
Study of BEBT-109 for lung cancer with EGFR exon 20 insertion mutation
This trial tests a new drug called BEBT-109 for people with a specific type of non-small cell lung cancer that has an EGFR exon 20 insertion mutation. It's for those who haven't had prior treatment for advanced or metastatic lung cancer, and it aims to see if the drug can help shrink or control the cancer.
Guangzhou, GuangdongAges 18 years+ - NCT06623487Recruiting
PET scan to guide immunotherapy for stage III lung cancer
This trial uses a special scan (68Ga-grazytracer PET) to see how well immunotherapy works for stage III non-small cell lung cancer before surgery or radiation. It aims to help doctors choose the best treatment for you.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06566443RecruitingPhase 1
Honokiol for early-stage lung cancer before surgery
This trial tests a natural compound called honokiol in people with early-stage non-small cell lung cancer who are scheduled for surgery. The goal is to see if honokiol can help shrink or control the tumor before it is removed.
Houston, TexasAges 18 years+ - NCT06472245RecruitingPhase 3
Cancer vaccine for lung cancer that stopped responding to immunotherapy
This trial tests a therapeutic cancer vaccine called OSE2101 for people with advanced non-small cell lung cancer whose tumors stopped responding to an immunotherapy drug. The vaccine is designed to help your immune system fight the cancer in a different way.
Beverly Hills, CaliforniaAges 18 years+ - NCT07469709Recruiting
Cancer risk study using genetics and monitoring
This study looks at genetic and other factors in people with certain cancers to better understand personal cancer risks and improve monitoring. It may help find ways to detect changes earlier.
Candiolo, TurinAges 18 years+ - NCT07128680RecruitingPhase 1
Immunotherapy with or without a gut bacteria pill for kidney cancer
This trial tests whether adding a live bacteria pill (EXL01) to standard immunotherapy drugs (nivolumab and ipilimumab) helps treat advanced or metastatic kidney cancer that has clear cells. You may join if you have not had prior immunotherapy and your cancer has not been treated before (except possibly after surgery).
Duarte, CaliforniaAges 18 years+ - NCT06866262RecruitingPhase 1/Phase 2
Inulin gel with immunotherapy for advanced kidney cancer
This trial tests whether adding an inulin gel to standard immunotherapy (ipilimumab and nivolumab) can help treat kidney cancer that has spread or cannot be removed. It is for people who have not had prior treatment for advanced disease.
Ann Arbor, MichiganAges 18 years+ - NCT07510334RecruitingPhase 2
VSV Virus Plus Immunotherapy for Advanced Kidney Cancer
This trial tests a combination of a special virus (VSV-IFNβ-NIS) with two immunotherapy drugs (ipilimumab and nivolumab) for people with advanced clear cell kidney cancer that hasn't been treated yet. It aims to see if this approach helps shrink tumors or slow the disease.
Rochester, MinnesotaAges 18 years+ - NCT04916990Recruiting
Care program for rural adults with several lung and head cancers
This study looks at how to improve care for adults with certain cancers who live in rural areas and may face access problems. It mainly focuses on people receiving cancer treatment at specific Colorado-area hospitals, and who are uninsured or underinsured.
Aurora, ColoradoAges 18–99 - NCT07871656Recruiting
Detecting lung cancer in non-smokers through urine
This study uses a simple urine test to help detect lung cancer in people who have never smoked but have a lung spot (nodule) on their CT scan. It may lead to a new, non-invasive way to check for cancer without needing a biopsy.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04335292RecruitingPhase 2
Osimertinib then chemotherapy for EGFR-mutated lung cancer
This Phase 2 study tests a treatment sequence starting with osimertinib, then using chemotherapy after it. It is meant for people with EGFR-mutated advanced lung cancer whose disease has come back or progressed, including a “rechallenge” attempt with osimertinib.
Vancouver, British ColumbiaAges 18 years+ - NCT07655622RecruitingPhase 1/Phase 2
Vebreltinib and furmonertinib for advanced EGFR-mutant lung cancer with high PD-L1
This trial tests a combination of two targeted drugs, vebreltinib and furmonertinib, for people with advanced non-small cell lung cancer that has an EGFR mutation and high levels of a protein called PD-L1. It may be an option for those who have not yet had treatment for advanced disease.
Nanchang, JianxiAges 18–75 - NCT07086456RecruitingPhase 2
Combination therapy for advanced lung cancer
This trial tests a combination of chemotherapy, radiation, and two targeted drugs (surufatinib and tislelizumab) for people with stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this approach works better than standard treatment.
Guangzhou, GuangdongAges 18–75 - NCT07063745RecruitingPhase 2/Phase 3
Comparing a new drug combo for advanced lung cancer with a specific gene change
This trial tests a new drug called Navlimetostat combined with pembrolizumab and chemotherapy versus a placebo with the same standard treatments. It is for people with metastatic non-small cell lung cancer that has a specific missing gene (MTAP deletion) and who have not had prior treatment for their advanced disease.
Anchorage, AlaskaAges 18 years+ - NCT07039994Recruiting
Early palliative care for advanced lung cancer using an e-health system
This study tests whether an online platform can help deliver early palliative care to people with advanced lung cancer. The goal is to see if this approach can improve quality of life and manage symptoms from the start of treatment.
Badalona, BarcelonaAges 18 years+
Hear when a new Lung Cancer Stage I trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer stage i?
- Yes. Clin2 currently lists 1,117 recruiting lung cancer stage i studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer stage i trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer stage i trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.